PRDX6 and breast carcinoma: Given the fact that PRDX6 is overexpressed predominantly in breast cancer, lung adenocarcinoma, and melanoma [202], their malignant phenotype may be associated with the anti-ferroptotic action attributed to the intrinsic activities of PRDX6 toward peroxidized phospholipids.